biostudies-literatureLipshultz SENICHD NIH HHSNIAID NIH HHSNHLBI NIH HHSNCI NIH HHS1042-9https://www.ebi.ac.uk/biostudies/studies/S-EPMC3341148biostudies-literatureUnknown30(10)<h4>Purpose</h4>Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy.<h4>Patients and methods</h4>Children with high-risk ALL were randomly assigned to receive doxorubicin alone (n = 100; 75 analyzed) or doxorubicin with dexrazoxane (n = 105; 81 analyzed). Echocardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy biomarker), and high-sensitivity C-reactive protein (hsCRP; inflammatory biomarker) were obtained before, during, and after treatment.<h4>Results</h4>cTnT levels were increased in 12% of cJournal of clinical oncology : official journal of the American Society of Clinical OncologyChanges in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.PMC3341148R13 HL087708CA068484CA127642R01 CA127642HL007188HD80002R01 HL053392F31 HL094100HL094100R01 HL072705HL053392K30 HL004537HL072705HL087000U01 AI050274HD052104AI50274HD052102R01 HL078522P01 CA068484R01 HL095127U01 HD052102U01 HD052104HL078522HL087708R01 HL087000HL004537HL095127HL079233T32 HL007188Sallan SENeuberg DSSchorin MAMichon BLipsitz SRDahlberg SEClavell LAScully RELaverdiere CLipshultz SEMiller TLRifai NColan SDHenkel JMAsselin BLAthale UHSilverman LBfalseChanges in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.<h4>Purpose</h4>Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy.<h4>Patients and methods</h4>Children with high-risk ALL were randomly assigned to receive doxorubicin alone (n = 100; 75 analyzed) or doxorubicin with dexrazoxane (n = 105; 81 analyzed). Echocardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy biomarker), and high-sensitivity C-reactive protein (hsCRP; inflammatory biomarker) were obtained before, during, and after treatment.<h4>Results</h4>cTnT levels were increased in 12% of c2012-01-01T00:00:00Z2012 Apr2025-05-29T20:05:26.003Z2025-05-29T20:05:26.003ZS-EPMC33411482237032610.1200/jco.2010.30.340410.1200/JCO.2010.30.3404